LW 402
Alternative Names: LW-402Latest Information Update: 11 Mar 2024
At a glance
- Originator Longwood Biopharma
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Atopic dermatitis; Rheumatoid arthritis; Vitiligo
Highest Development Phases
- Phase III Rheumatoid arthritis
- Phase II Atopic dermatitis; Vitiligo
Most Recent Events
- 27 Feb 2024 LW 402 is available for licensing as of 27 Feb 2024. https://www.lwbpsh.com/en/research#collaboration
- 26 Feb 2024 Phase-II clinical trials in Vitiligo (PO) (Longwood Biopharma website, February 2024)
- 26 Feb 2024 Phase-III clinical trials in Rheumatoid arthritis (PO) (Longwood Biopharma website, February 2024)